Pyrazinamide-induced Hyperuricemia in Pulmonary Tuberculosis Patients.
Journal
International journal of mycobacteriology
ISSN: 2212-554X
Titre abrégé: Int J Mycobacteriol
Pays: India
ID NLM: 101615660
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
received:
20
05
2024
accepted:
25
08
2024
medline:
15
9
2024
pubmed:
15
9
2024
entrez:
15
9
2024
Statut:
ppublish
Résumé
Pyrazinamide is one of the antitubercular drugs used for 2 months in the intensive phase. One of the adverse effects of pyrazinamide is hyperuricemia, with a symptom of arthralgia. This study aims to analyze the incidence of hyperuricemia and arthralgia and their causality in pulmonary tuberculosis (TB) patients undergoing treatment in the intensive phase. It was an analytic observational study with a prospective cohort design. Three ml of blood from each pulmonary TB patient was withdrawn to examine uric acid levels before and after 2 months of treatment with pyrazinamide. The Wilcoxon test was used to analyze changes in uric acid levels and the Chi-square test to analyze the association between uric acid levels and arthralgia. Naranjo algorithm is used to analyze the causality of hyperuricemia. Twenty pulmonary TB patients met the inclusion criteria in this study. Eight out of 12 (60%) TB patients showed uric acid levels ≥7 mg/dl and 8 of them (66.6%) showed symptoms of arthralgia. The median uric acid level increased significantly before (5.14 mg/dl) and after 2 months of treatment (7.74 mg/dl), P-value = 0.001. Uric acid levels ≥7 mg/dl were significantly associated with arthralgia (P-value = 0.017; odds ratio 14.00; 95% confidence interval 1.25-156.61). Based on the Naranjo algorithm, those with hyperuricemia, eight and four patients had a total score of 7 and 8, respectively, which are classified as probable. Uric acid levels significantly increased during the intensive phase. Pulmonary TB patients with hyperuricemia are a risk factor for arthralgia.
Sections du résumé
BACKGROUND
BACKGROUND
Pyrazinamide is one of the antitubercular drugs used for 2 months in the intensive phase. One of the adverse effects of pyrazinamide is hyperuricemia, with a symptom of arthralgia. This study aims to analyze the incidence of hyperuricemia and arthralgia and their causality in pulmonary tuberculosis (TB) patients undergoing treatment in the intensive phase.
METHODS
METHODS
It was an analytic observational study with a prospective cohort design. Three ml of blood from each pulmonary TB patient was withdrawn to examine uric acid levels before and after 2 months of treatment with pyrazinamide. The Wilcoxon test was used to analyze changes in uric acid levels and the Chi-square test to analyze the association between uric acid levels and arthralgia. Naranjo algorithm is used to analyze the causality of hyperuricemia.
RESULTS
RESULTS
Twenty pulmonary TB patients met the inclusion criteria in this study. Eight out of 12 (60%) TB patients showed uric acid levels ≥7 mg/dl and 8 of them (66.6%) showed symptoms of arthralgia. The median uric acid level increased significantly before (5.14 mg/dl) and after 2 months of treatment (7.74 mg/dl), P-value = 0.001. Uric acid levels ≥7 mg/dl were significantly associated with arthralgia (P-value = 0.017; odds ratio 14.00; 95% confidence interval 1.25-156.61). Based on the Naranjo algorithm, those with hyperuricemia, eight and four patients had a total score of 7 and 8, respectively, which are classified as probable.
CONCLUSION
CONCLUSIONS
Uric acid levels significantly increased during the intensive phase. Pulmonary TB patients with hyperuricemia are a risk factor for arthralgia.
Identifiants
pubmed: 39277890
doi: 10.4103/ijmy.ijmy_178_23
pii: 01929415-202413030-00008
doi:
Substances chimiques
Pyrazinamide
2KNI5N06TI
Antitubercular Agents
0
Uric Acid
268B43MJ25
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
282-287Informations de copyright
Copyright © 2024 Copyright: © 2024 International Journal of Mycobacteriology.
Références
World Health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022.
Salehi M, Shahsiah R, Khorasani KM, Hasannezhad M, Rahimi A, Yousefi B, et al. Identification of Mycobacterium tuberculosis in pulmonary and extrapulmonary specimens of Iranian hospitalized patients during 2017-2021. Int J Mycobacteriol 2023;12:23-7.
World Health Organization. WHO Consolidated Guidelines on Tuberculosis Module 4 – Treatment Drug-Susceptible Tuberculosis Treatment. Geneva: World Health Organization; 2021.
Calderwood CJ, Wilson JP, Fielding KL, Harris RC, Karat AS, Mansukhani R, et al. Dynamics of sputum conversion during effective tuberculosis treatment: A systematic review and meta-analysis. PLoS Med 2021;18:e1003566.
Pietersen E, Anderson K, Cox H, Dheda K, Bian A, Shepherd BE, et al. Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa. PLoS One 2023;18:e0281097.
Gopal P, Grüber G, Dartois V, Dick T. Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide. Trends Pharmacol Sci 2019;40:930-40.
Lucena SM, Alberio CA, Pinto AC, Vieira JL. Serum pyrazinamide concentrations in patients with pulmonary tuberculosis. J Bras Pneumol 2019;45:e20180254.
Ha YJ, Chung SW, Lee JH, Kang EH, Lee YJ, Song YW. Clinical features and risk factors for gout attacks during anti-tuberculosis treatment: A case-control study in South Korea. Int J Rheum Dis 2019;22:1905-11.
Thumamo Pokam BD, Enoh JE, Eyo AO, Umoh NO, Guemdjom PW. Uric acid levels in patients on antituberculosis drugs in the Southwest region of Cameroon. Int J Mycobacteriol 2018;7:89-91.
Chandra Mohapatra G, Javed Khan M, Nayak S, Chandra Mohapatra D. Incidence of hyperuricemia and gouty arthritis in patients taking pyrazinamide for the treatment of tuberculosis. Ann Rom Soc Cell Biol 2021;25:324-8.
Murali M, Suppes SL, Feldman K, Goldman JL. Utilization of the Naranjo scale to evaluate adverse drug reactions at a free-standing children’s hospital. PLoS One 2021;16:e0245368.
Ko Y, Kim C, Park YB, Mo EK, Moon JW. Changes in nutritional status in pulmonary tuberculosis: Longitudinal changes in BMI according to acid-fast bacilli smear positivity. J Clin Med 2020;9:4082.
Putra ON, Yulistiani Y, Soedarsono S, Subay S. Early efficacy of individual regimens containing bedaquiline in patients with drug resistant tuberculosis. Asian Pac J Trop Med 2023;16:169-75.
Putra ON, Yulistiani Y, Soedarsono S, Subay S. Baseline glycated hemoglobin and potassium level correlated with pretreatment QT-corrected interval among patients with diabetic drug-resistant tuberculosis. Int J Mycobacteriol 2023;12:241-7.
Kornfeld H, Sahukar SB, Procter-Gray E, Kumar NP, West K, Kane K, et al. Impact of diabetes and low body mass index on tuberculosis treatment outcomes. Clin Infect Dis 2020;71:e392-8.
George JT, Miraclin AT, Sathyendra S, Michael JS, Prasad J, Rebekah G. Pulmonary tuberculosis and diabetes mellitus: Clinical profile and outcomes. Int J Mycobacteriol 2022;11:400-6.
Chen Z, Liu Q, Song R, Zhang W, Wang T, Lian Z, et al. The association of glycemic level and prevalence of tuberculosis: A meta-analysis. BMC Endocr Disord 2021;21:123.
Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology (Oxford) 2017;56:679-88.
García-Nieto VM, Claverie-Martín F, Moraleda-Mesa T, Perdomo-Ramírez A, Tejera-Carreño P, Cordoba-Lanus E, et al. Gout associated with reduced renal excretion of uric acid. Renal tubular disorder that nephrologists do not treat. Nefrologia (Engl Ed) 2022;42:273-9.
Saito N, Yoshii Y, Kaneko Y, Nakashima A, Horikiri T, Saito Z, et al. Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease. BMC Infect Dis 2019;19:374.
Shi W. Activity of pyrazinamide against Mycobacterium tuberculosis at neutral pH in PZA-S1 minimal medium. Antibiotics (Basel) 2021;10:909.
Tátrai P, Erdő F, Dörnyei G, Krajcsi P. Modulation of urate transport by drugs. Pharmaceutics 2021;13:899.
Inayat N, Shah RH, Lakhair MA, Sahito R. Hyperuricemia and arthralgia during pyrazinamide therapy in patients with pulmonary tuberculosis. Pak J Chest Med 2016;22:154-8.
Emorinken A, Ugheoke AJ. Pyrazinamide-induced acute gouty arthritis: A case report. Int J Res Med Sci 2022;10:526.
Pichholiya M, Yadav AK, Luhadia SK, Tahashildar J, Aseri ML. A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients. Indian J Pharmacol 2016;48:522-5.
Stemkens R, Litjens CH, Dian S, Ganiem AR, Yunivita V, van Crevel R, et al. Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment. Int J Antimicrob Agents 2019;54:371-4.
Zhang N, Savic RM, Boeree MJ, Peloquin CA, Weiner M, Heinrich N, et al. Optimising pyrazinamide for the treatment of tuberculosis. Eur Respir J 2021;58:13-20.
Kimura Y, Tsukui D, Kono H. Uric acid in inflammation and the pathogenesis of atherosclerosis. Int J Mol Sci 2021;22:12394.
Kwon BS, Kim Y, Lee SH, Lim SY, Lee YJ, Park JS, et al. The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. PLoS One 2020;15:e0236109.
Panda BK, Suryawanshi VR, Bargaje M, Sathiyanarayanan L. Pyrazinamide-induced polyarthralgia and myalgia in a case of stable chronic kidney disease. Indian J Pharm Pract 2022;15:49-52.